Silence Therapeutics (SLN) Price & Analysis

Compare

182 Followers

SLN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.97 - $20.48

Previous CloseN/A

Volume50.54K

Average Volume (3M)69.65K

Market Cap

$243.73M

Enterprise Value$159.79M

Total Cash (Recent Filing)$114.16M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.21

Next Earnings

Nov 18, 2025

EPS Estimate

-0.19

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.19

Shares Outstanding47,233,948

10 Day Avg. Volume58,637

30 Day Avg. Volume69,654

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.66

Enterprise Value/Revenue6.18

Enterprise Value/Gross Profit7.50

Enterprise Value/Ebitda-2.83

Forecast

1Y Price Target

$38.33

Price Target Upside637.12% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical Program AdvancementsSilence Therapeutics is advancing its clinical programs with divesiran showing strong potential in controlling polycythemia vera without the need for phlebotomy.

Financial StabilitySilence Therapeutics has a cash runway extending into 2028, providing financial stability to focus on high-value programs and sustained value creation.

Market OpportunitiesDespite PV's increasingly crowded landscape, PV remains a large commercial opportunity given the high unmet need and significant sales potential.

Bears Say

Competitive LandscapeDespite PV's increasingly crowded landscape, PV remains a large commercial opportunity given high unmet need, evidenced by significant sales and partnerships.

Partnership UncertaintyThe start of a Ph3 cardiovascular outcomes study (CVOT) for zerlasiran will depend on securing a partner.

Valuation ConcernsShares currently do not reflect any value for zerlasiran as partnering discussions remain ongoing.

Silence Therapeutics News

Private Markets: Canva draws attention as IPO candidate following Figma debut

Canva is gaining significant attention as a potential IPO candidate. The rising investor enthusiasm around the design-software giant...

21d ago

CAI

Silence Therapeutics reports Q2 EPS (19c), consensus (21c)

Reports Q2 revenue $224,000, consensus $3.38M. “The updated data we presented at EHA this past quarter were highly...

22d ago

SLN

Michael Davidson Resigns from Silence Therapeutics Board

The latest announcement is out from Silence Therapeutics ( ($SLN) ). On August 11, 2025, Michael Davidson resigned...

15d ago

SLN

Buy Rating for Silence Therapeutics: Promising siRNA Therapies and Strategic Pipeline Prioritization

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Silence Therapeutics, retaining the price target of...

18d ago

SLN

Silence Therapeutics Reports Q2 2025 Progress and Financials

Silence Therapeutics Plc ( ($SLN) ) has released its Q2 earnings. Here is a breakdown of the information...

21d ago

SLN

Silence Therapeutics Passes Key Resolutions at AGM

Silence Therapeutics ( ($SLN) ) just unveiled an announcement. On June 26, 2025, Silence Therapeutics held its Annual...

2M ago

SLN

Buy Rating on Silence Therapeutics: Promising Developments in Divesiran and Zerlasiran Programs

Silence Therapeutics (SLN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday....

3M ago

SLN

Promising Phase 1 Data and Strong Mechanistic Rationale Justify Buy Rating for Silence Therapeutics’ Divesiran in Polycythemia Vera

H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on SLN stock, giving a Buy rating today....

3M ago

SLN

Positive Outlook for Silence Therapeutics: Promising Clinical Data and Progress in SANRECO Study Justify Buy Rating

Morgan Stanley analyst Michael Ulz has maintained their bullish stance on SLN stock, giving a Buy rating today....

3M ago

SLN

Silence Therapeutics presents additional Phase 1 data highlighting Divesiran

Silence Therapeutics (SLN) “presented additional data showcasing the SANRECO Phase 1 study of divesiran in patients with polycythemia...

3M ago

SLN

Silence Therapeutics Reports Q1 2025 Financial Results

Silence Therapeutics Plc ( ($SLN) ) has released its Q1 earnings. Here is a breakdown of the information...

4M ago

SLN

Silence Therapeutics: Strategic Positioning and Growth Potential Justify Buy Rating

Analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Silence Therapeutics (SLN – Research Report) and...

4M ago

SLN

Silence Therapeutics reports Q1 EPS (20c), consensus (41c)

Reports Q1 revenue $142,000, consensus $3.58M. “Silence delivered another strong quarter focused on clinical and operational execution,” said...

4M ago

SLN

Silence Therapeutics Announces Board Changes and New Director

Silence Therapeutics ( ($SLN) ) just unveiled an announcement. On May 5, 2025, Silence Therapeutics announced the retirement...

4M ago

SLN

SLN FAQ

What was Silence Therapeutics’s price range in the past 12 months?

Silence Therapeutics lowest stock price was $1.97 and its highest was $20.48 in the past 12 months.

What is Silence Therapeutics’s market cap?

Silence Therapeutics’s market cap is $243.73M.

When is Silence Therapeutics’s upcoming earnings report date?

Silence Therapeutics’s upcoming earnings report date is Nov 18, 2025 which is in 81 days.

How were Silence Therapeutics’s earnings last quarter?

Silence Therapeutics released its earnings results on Aug 07, 2025. The company reported -$0.19 earnings per share for the quarter, missing the consensus estimate of -$0.132 by -$0.058.

Is Silence Therapeutics overvalued?

According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Silence Therapeutics pay dividends?

Silence Therapeutics does not currently pay dividends.

What is Silence Therapeutics’s EPS estimate?

Silence Therapeutics’s EPS estimate is -0.19.

How many shares outstanding does Silence Therapeutics have?

Silence Therapeutics has 47,233,948 shares outstanding.

What happened to Silence Therapeutics’s price movement after its last earnings report?

Silence Therapeutics reported an EPS of -$0.19 in its last earnings report, missing expectations of -$0.132. Following the earnings report the stock price went up 1.128%.

Which hedge fund is a major shareholder of Silence Therapeutics?

Currently, no hedge funds are holding shares in SLN

Silence Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-99.23%

Trailing 12-Months

Asset Growth

-30.71%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.

Silence Therapeutics (SLN) Earnings & Revenues

Historic Earnings Reports

SLN Stock 12 Month Forecast

Average Price Target

$38.33

▲(637.12% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","76":"$76","19.75":"$19.75","38.5":"$38.5","57.25":"$57.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$75.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":38.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$38.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,19.75,38.5,57.25,76],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.17,11.464615384615385,16.75923076923077,22.053846153846152,27.348461538461535,32.64307692307692,37.93769230769231,43.23230769230769,48.526923076923076,53.82153846153846,59.11615384615384,64.41076923076922,69.70538461538462,{"y":75,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.17,8.643846153846154,11.117692307692307,13.59153846153846,16.065384615384616,18.53923076923077,21.013076923076923,23.486923076923077,25.96076923076923,28.434615384615384,30.908461538461538,33.38230769230769,35.856153846153845,{"y":38.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.17,6.849230769230769,7.5284615384615385,8.207692307692307,8.886923076923077,9.566153846153846,10.245384615384616,10.924615384615384,11.603846153846153,12.283076923076923,12.962307692307693,13.641538461538461,14.32076923076923,{"y":15,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":19.79,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.09,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.23,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.68,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.18,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.88,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.42,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.73,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.92,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.17,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >